271 related articles for article (PubMed ID: 34589288)
1.
Kawase W; Kurotaki D; Suzuki Y; Ishihara H; Ban T; Sato GR; Ichikawa J; Yanai H; Taniguchi T; Tsukahara K; Tamura T
Mol Ther Nucleic Acids; 2021 Sep; 25():708-715. PubMed ID: 34589288
[TBL] [Abstract][Full Text] [Related]
2. Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid.
Suzuki Y; Ishihara H
Int J Pharm; 2016 Aug; 510(1):350-8. PubMed ID: 27374199
[TBL] [Abstract][Full Text] [Related]
3. Engineered ionizable lipid nanoparticles mediated efficient siRNA delivery to macrophages for anti-inflammatory treatment of acute liver injury.
Zhang H; Ding F; Zhu Z; Sun Q; Yang C
Int J Pharm; 2023 Jan; 631():122489. PubMed ID: 36521639
[TBL] [Abstract][Full Text] [Related]
4. Lipid Nanoparticle (LNP) Chemistry Can Endow Unique
Johnson LT; Zhang D; Zhou K; Lee SM; Liu S; Dilliard SA; Farbiak L; Chatterjee S; Lin YH; Siegwart DJ
Mol Pharm; 2022 Nov; 19(11):3973-3986. PubMed ID: 36154076
[TBL] [Abstract][Full Text] [Related]
5. Molecular-Level Structural Analysis of siRNA-Loaded Lipid Nanoparticles by
Ueda K; Sakagawa Y; Saito T; Fujimoto T; Nakamura M; Sakuma F; Kaneko S; Tokumoto T; Nishimura K; Takeda J; Arai Y; Yamamoto K; Ikeda Y; Higashi K; Moribe K
Mol Pharm; 2023 Sep; 20(9):4729-4742. PubMed ID: 37606988
[No Abstract] [Full Text] [Related]
6. Effect of the nanoformulation of siRNA-lipid assemblies on their cellular uptake and immune stimulation.
Kubota K; Onishi K; Sawaki K; Li T; Mitsuoka K; Sato T; Takeoka S
Int J Nanomedicine; 2017; 12():5121-5133. PubMed ID: 28790820
[TBL] [Abstract][Full Text] [Related]
7. Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells.
Basha G; Novobrantseva TI; Rosin N; Tam YY; Hafez IM; Wong MK; Sugo T; Ruda VM; Qin J; Klebanov B; Ciufolini M; Akinc A; Tam YK; Hope MJ; Cullis PR
Mol Ther; 2011 Dec; 19(12):2186-200. PubMed ID: 21971424
[TBL] [Abstract][Full Text] [Related]
8. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
[TBL] [Abstract][Full Text] [Related]
9. Airway epithelial cell-specific delivery of lipid nanoparticles loading siRNA for asthma treatment.
Zhang M; Jiang H; Wu L; Lu H; Bera H; Zhao X; Guo X; Liu X; Cun D; Yang M
J Control Release; 2022 Dec; 352():422-437. PubMed ID: 36265740
[TBL] [Abstract][Full Text] [Related]
10. Production of siRNA-Loaded Lipid Nanoparticles using a Microfluidic Device.
Maeki M; Okada Y; Uno S; Niwa A; Ishida A; Tani H; Tokeshi M
J Vis Exp; 2022 Mar; (181):. PubMed ID: 35404350
[TBL] [Abstract][Full Text] [Related]
11. Identification of a potent ionizable lipid for efficient macrophage transfection and systemic anti-interleukin-1β siRNA delivery against acute liver failure.
Ding F; Zhang H; Li Q; Yang C
J Mater Chem B; 2021 Jul; 9(25):5136-5149. PubMed ID: 34132324
[TBL] [Abstract][Full Text] [Related]
12. Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus.
Sato Y; Matsui H; Yamamoto N; Sato R; Munakata T; Kohara M; Harashima H
J Control Release; 2017 Nov; 266():216-225. PubMed ID: 28986168
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of negative charges of siRNA results in improved safety and efficient gene silencing activity of lipid nanoparticles loaded with high levels of siRNA.
Sato Y; Matsui H; Sato R; Harashima H
J Control Release; 2018 Aug; 284():179-187. PubMed ID: 29936118
[TBL] [Abstract][Full Text] [Related]
14. Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles.
Evers MJW; Du W; Yang Q; Kooijmans SAA; Vink A; van Steenbergen M; Vader P; de Jager SCA; Fuchs SA; Mastrobattista E; Sluijter JPG; Lei Z; Schiffelers R
J Control Release; 2022 Mar; 343():207-216. PubMed ID: 35077739
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Lipid Nanoparticles Containing Ionizable Cationic Lipids Using Design-of-Experiments Approach.
Terada T; Kulkarni JA; Huynh A; Chen S; van der Meel R; Tam YYC; Cullis PR
Langmuir; 2021 Jan; 37(3):1120-1128. PubMed ID: 33439022
[TBL] [Abstract][Full Text] [Related]
16. Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells.
Khare P; Dave KM; Kamte YS; Manoharan MA; O'Donnell LA; Manickam DS
AAPS J; 2021 Dec; 24(1):8. PubMed ID: 34873640
[TBL] [Abstract][Full Text] [Related]
17. Enhanced Delivery of siRNA to Retinal Ganglion Cells by Intravitreal Lipid Nanoparticles of Positive Charge.
Huang X; Chau Y
Mol Pharm; 2021 Jan; 18(1):377-385. PubMed ID: 33295773
[TBL] [Abstract][Full Text] [Related]
18. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
19. siRNA delivery to lymphatic endothelial cells via ApoE-mediated uptake by lipid nanoparticles.
Sakurai Y; Yoshikawa K; Arai K; Kazaoka A; Aoki S; Ito K; Nakai Y; Tange K; Furihata T; Tanaka H; Akita H
J Control Release; 2023 Jan; 353():125-133. PubMed ID: 36414194
[TBL] [Abstract][Full Text] [Related]
20. Stabilization of Ostwald ripening in low molecular weight amino lipid nanoparticles for systemic delivery of siRNA therapeutics.
Gindy ME; Feuston B; Glass A; Arrington L; Haas RM; Schariter J; Stirdivant SM
Mol Pharm; 2014 Nov; 11(11):4143-53. PubMed ID: 25317715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
